CARM1 and ovarian cancer: In a recent study, immunocompromised mice that received orthotopic injection of Coactivator-Associated Arginine Methyltransferase 1 (CARM1)-high ovarian cancer cells showed enhanced therapeutic responses to the IRE1α RNase inhibitor B-I09 compared to mice with CARM1-low ovarian tumors [192].